Zydus to buy Assertio for $166m cash; closes in Q2 2026

Deal announced and why it matters

Assertio Holdings, Inc. (Nasdaq: ASRT) said its board has approved a definitive agreement for Zydus Worldwide DMCC, a subsidiary of Zydus Lifesciences Limited, to acquire all outstanding Assertio shares for $13.50 per share in cash. The transaction is structured as an all-cash tender offer followed by a second-step merger at the same price. Assertio said the implied total consideration is approximately $166.4 million.

The announcement is notable because it follows Assertio’s earlier sale agreement with Garda Therapeutics. After an engagement process set out in a revised merger agreement with Garda (the “Garda Merger Agreement”), Assertio’s board determined that the Zydus proposal qualifies as a “Superior Proposal” and authorised termination of the Garda agreement announced on May 4, 2026.

Key terms: $13.50 per share tender offer

Under the terms described by Assertio, Zydus will “promptly commence” a tender offer to buy all outstanding Assertio common stock at $13.50 per share in cash, without interest. The Assertio board unanimously recommends that stockholders tender their shares into the offer.

The transaction is expected to close in the second quarter of 2026, subject to customary closing conditions, including the tender of a majority of Assertio’s outstanding shares. Assertio also said no regulatory approvals are expected to be required. After the tender offer is completed, Zydus intends to acquire any remaining shares through a second-step merger at $13.50 per share.

How Zydus topped Garda’s bid

Assertio disclosed that the $13.50-per-share offer represents multiple premiums versus both the prior Garda pricing and the company’s unaffected share price. Specifically, Assertio said the Zydus price implies:

• a 30.6% premium to the $18.00-per-share all-cash transaction with Garda announced on April 8, 2026
• a 7.8% premium to the $11.80-per-share all-cash transaction with Garda announced on May 4, 2026
• a 75.8% premium to Assertio’s unaffected closing stock price on March 20, 2026, described as the day before significant share price and trading volume movement

A Dow Jones Newswires item in the provided text also characterised the premium to the unaffected price as about 76%.

Board process and “Superior Proposal” finding

Assertio said the Zydus deal emerged following an engagement process under the revised Garda Merger Agreement. After reviewing the proposal, the board concluded the Zydus offer constituted a “Superior Proposal” under that agreement and authorised Assertio to terminate the Garda deal and enter into the Zydus transaction.

Assertio also highlighted deal certainty elements, stating the Zydus offer “has no financing contingencies, requires no third-party financing, and is fully guaranteed by a creditworthy Zydus entity,” giving Assertio recourse in the event of a breach or failure to close.

Closing timeline, conditions, and delisting

Assertio expects the deal to close in Q2 2026 if the tender offer conditions are met. A key condition is the tender of a majority of the company’s outstanding shares. The company indicated that no regulatory approvals are expected, which can reduce execution risk compared with transactions requiring antitrust or other clearances.

Upon completion of the transaction, Assertio’s common stock will no longer be listed on Nasdaq. That implies a move from a publicly traded U.S. listing to ownership under Zydus through its acquisition vehicle.

What filings investors should watch

Assertio said it will file a current report on Form 8-K with the U.S. Securities and Exchange Commission containing a summary of the terms and conditions of the Zydus transaction. It also expects to file a Schedule 14D-9 in connection with the tender offer, which typically includes the board’s recommendation and additional context on the strategic review.

Assertio also emphasised that the tender offer “has not yet commenced,” and that the communication is for information purposes only and not an offer to buy or a solicitation to sell securities. The tender offer materials are expected to be filed by Zydus Worldwide DMCC and its wholly owned acquisition subsidiary, Zara Merger Sub, Inc.

Offer comparison table

Market reaction: Zydus Lifesciences share move in India

The provided text also included a snapshot of Zydus Lifesciences Ltd trading in the Indian market. As of the latest trading session cited, Zydus Lifesciences was at ₹930.65, down ₹26.29 or 2.74% from the previous close. The stock traded between ₹928.60 and ₹963.95 during the day.

Over the past year, the stock delivered a return of 8.14%, and in the last month it returned 3.74%, as stated in the same snapshot. The counters listed were BSE: 532321 and NSE: ZYDUSLIFE.

Background: Zydus’ recent M&A references in the text

Beyond Assertio, the provided material referenced other deal activity and deal discussions linked to Zydus. It said Zydus Lifesciences “eyes acquisition of US firm Ardelyx” with a proposed purchase price range of $1.2-2.5 billion, and that the transaction would be funded through a ₹5,000 crore equity raise via a QIP and internal cash accruals, citing “people” in the text.

Separately, the text described Zydus’ acquisition of a majority stake in Amplitude Surgical. Zydus entered agreements on March 11, 2025 to acquire 85.6% of Amplitude Surgical at €6.25 per share for a total consideration of €256 million, and said the block acquisition completed on July 29, 2025. It also described a simplified mandatory tender offer for the remaining shares at the same €6.25 per share, subject to French market authority clearance.

Market impact and analysis

For Assertio shareholders, the key market impact described in the announcement is the price uplift versus the earlier Garda terms and the unaffected reference price date. The board’s unanimous recommendation to tender, the all-cash consideration, and the stated lack of financing contingencies are central elements of the risk assessment for investors.

For Zydus Lifesciences investors tracking overseas expansion, the structure highlights a clear cash-out transaction size of about $166.4 million. The Indian market snapshot in the provided text shows Zydus Lifesciences trading lower on the day at ₹930.65, though the material does not attribute that move to this specific transaction.

Conclusion and next steps

Assertio’s board has approved the Zydus offer and authorised termination of its earlier agreement with Garda after determining the Zydus proposal is superior under the revised terms. The next formal steps, as described, are the commencement of the tender offer, the filing of required SEC documents including an 8-K and Schedule 14D-9, and meeting the condition that a majority of shares are tendered. Assertio said the deal is expected to close in the second quarter of 2026, after which the stock would no longer be listed on Nasdaq.